| ABOUT BAYBIOGET INVOLVEDEVENT CENTER
MEMBER CENTERINFORMATION CENTERMEDIA CENTER |
Hepatitis C: in Search of a Cure Sponsored by:
![]() Where We Were, Where We Are, Where We are Going According to National Institutes of Health (NIH), hepatitis C is currently estimated to affect over 4 million Americans, making it one of the nation's most common and difficult to treat blood-borne infections. With no vaccine on the immediate horizon and current treatments deemed difficult to tolerate, this disease has become a central focus and opportunity for many Northern California Life Science Companies. Current therapies to treat this disease focus on immune modulators in combination with ribavirin. Although this has been a mainstay of treatment options for Hepatitis C, it has limited ability to work for all patients. Promising new treatments are currently under study by our local life science companies to treat and cure this disease. Please join us to learn their approach and hope; their innovation and desire; and future products in the pipeline. Moderator:Emily Hua Vice President, Brand Management Practice, Campbell Alliance Panel Speakers: Richard Colonno, PhD Chief Scientific Officer, Presidio Pharmaceuticals, Inc. Jon C. Mirsalis Managing Director, Division Operations Director, Preclinical Development, Biosciences Division, SRI International Israel Rios, MD Chief Medical Officer, SciClone Pharmaceuticals, Inc. Roy Wu Vice President, Business Development, GeneLabs Technologies, Inc.
Registrations: If you are an employee of a Partner or Sponsor company, please contact Program Director, Misha Tsirulnikov to obtain your complimentary registration. On-line reservations: CLICK HERE Reservations by mail or fax: CLICK HERE
Is your company a member? Click here to check. See how your company can save money by becoming a BayBio member! |